{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:48:42Z","timestamp":1761562122147,"version":"3.41.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T00:00:00Z","timestamp":1466726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T00:00:00Z","timestamp":1466726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s12325-016-0362-1","type":"journal-article","created":{"date-parts":[[2016,6,25]],"date-time":"2016-06-25T18:14:08Z","timestamp":1466878448000},"page":"1316-1330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States"],"prefix":"10.1007","volume":"33","author":[{"given":"Sammy","family":"Saab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suchin","family":"Virabhak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Paris\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Misurski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri Sanchez","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Juday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,24]]},"reference":[{"key":"362_CR1","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1002\/hep.26218","volume":"57","author":"H Razavi","year":"2013","unstructured":"Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57:2164\u201370.","journal-title":"Hepatology"},{"issue":"10","key":"362_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","volume":"144","author":"GL Armstrong","year":"2006","unstructured":"Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705\u201314 (United States).","journal-title":"Ann Intern Med"},{"key":"362_CR3","unstructured":"CDC. Disease burden from viral hepatitis A, B, and C in the United States. http:\/\/www.cdc.gov\/hepatitis\/PDFs\/disease_burden.pdf. Accessed 15 June 2016."},{"key":"362_CR4","doi-asserted-by":"publisher","first-page":"12132","DOI":"10.3748\/wjg.v20.i34.12132","volume":"20","author":"LN Clausen","year":"2014","unstructured":"Clausen LN, Lundbo LF, Benfield T. Hepatitis C virus infection in the human immunodeficiency virus infected patient. World J Gastroenterol. 2014;20:12132\u201343.","journal-title":"World J Gastroenterol"},{"key":"362_CR5","unstructured":"Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data\u2014United States and 6 dependent areas\u20142012. HIV Surveillance Supplemental Report 2014;19(3). http:\/\/www.cdc.gov\/hiv\/library\/reports\/surveillance\/. Accessed 30 May 2015."},{"issue":"4","key":"362_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jama.2014.7734","volume":"312","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312(4):353\u201361 (United States).","journal-title":"JAMA."},{"key":"362_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1473-3099(13)70149-X","volume":"13","author":"M Sulkowski","year":"2013","unstructured":"Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13:597\u2013605.","journal-title":"Lancet Infect Dis."},{"issue":"2","key":"362_CR8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","volume":"159","author":"MS Sulkowski","year":"2013","unstructured":"Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86\u201396 (United States).","journal-title":"Ann Intern Med."},{"key":"362_CR9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"M Sulkowski","year":"2015","unstructured":"Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8\u00a0weeks versus 12\u00a0weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV\/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1087\u201397.","journal-title":"Lancet"},{"issue":"12","key":"362_CR10","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2015.1328","volume":"313","author":"MS Sulkowski","year":"2015","unstructured":"Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223\u201331 (United States).","journal-title":"JAMA"},{"issue":"22","key":"362_CR11","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1001\/archinte.162.22.2545","volume":"162","author":"FC Kuehne","year":"2002","unstructured":"Kuehne FC, Bethe U, Freedberg K, Goldie SJ. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med. 2002;162(22):2545\u201356.","journal-title":"Arch Intern Med"},{"issue":"4","key":"362_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jcv.2006.04.008","volume":"36","author":"J Hornberger","year":"2006","unstructured":"Hornberger J, Torriani FJ, Dieterich DT, et al. Cost-effectiveness of peginterferon alfa-2a (40\u00a0kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J Clin Virol. 2006;36(4):283\u201391 (Netherlands).","journal-title":"J Clin Virol."},{"issue":"3","key":"362_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.amjmed.2006.06.036","volume":"120","author":"NG Campos","year":"2007","unstructured":"Campos NG, Salomon JA, Servoss JC, et al. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med. 2007;120(3):272\u20139 (United States).","journal-title":"Am J Med."},{"key":"362_CR14","unstructured":"AASLD-IDSA. HCV testing and linkage to care. Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org\/full-report\/hcv-testing-and-linkage-care. Accessed 30 May 2015."},{"key":"362_CR15","volume-title":"Sofosbuvir and Peginterferon alfa-2a\/Ribavirin Treatment of na\u00efve Genotype 1\u20134 HCV infected patients that are coinfected with HIV","author":"M Rodriguez-Torres","year":"2013","unstructured":"Rodriguez-Torres M, Rodriguez-Orengo J, Gaggar A, et al. Sofosbuvir and Peginterferon alfa-2a\/Ribavirin Treatment of na\u00efve Genotype 1\u20134 HCV infected patients that are coinfected with HIV. San Francisco: ID Week; 2013."},{"key":"362_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/QAI.0000000000000516","volume":"68","author":"M Rodriguez-Torres","year":"2015","unstructured":"Rodriguez-Torres M, Gaggar A, Shen G, et al. Sofosbuvir for chronic hepatitis C virus infection genotype 1\u20134 in patients coinfected with HIV. J Acquir Immune Defic Syndr. 2015;68:543\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"362_CR17","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S0140-6736(14)62483-1","volume":"385","author":"JM Molina","year":"2015","unstructured":"Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015;385:1098\u2013106.","journal-title":"Lancet"},{"key":"362_CR18","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jama.2015.1373","volume":"313","author":"A Osinusi","year":"2015","unstructured":"Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313:1232\u20139.","journal-title":"JAMA"},{"issue":"4","key":"362_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","volume":"156","author":"S Liu","year":"2012","unstructured":"Liu S, Cipriano LE, Holodniy M, et al. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156(4):279\u201390 (United States).","journal-title":"Ann Intern Med."},{"key":"362_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/apt.12871","volume":"40","author":"S Saab","year":"2014","unstructured":"Saab S, Gordon SC, Park H, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon\/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2014;40:657\u201375.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"362_CR21","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1086\/321909","volume":"33","author":"CS Graham","year":"2001","unstructured":"Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562\u20139 (United States).","journal-title":"Clin Infect Dis."},{"issue":"15","key":"362_CR22","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1097\/QAD.0b013e32830e6d51","volume":"22","author":"HH Thein","year":"2008","unstructured":"Thein HH, Yi Q, Dore GJ, et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979\u201391 (England).","journal-title":"AIDS."},{"issue":"1","key":"362_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1365-2893.2005.00575.x","volume":"12","author":"M Wright","year":"2005","unstructured":"Wright M, Forton D, Main J, Goldin R, Torok E, Tedder R, Grant P, Thursz M, Naoumov N, Millson C, Mills PR, Bassendine M, Thomas HC, UK Mild HCV Trial investigators. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. J Viral Hepat. 2005;12(1):58\u20136.","journal-title":"J Viral Hepat"},{"issue":"17","key":"362_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15170","volume":"15","author":"D Hartwell","year":"2011","unstructured":"Hartwell D, Jones J, Baxter L, et al. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV\/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess. 2011;15(17):1\u2013210. doi:10.3310\/hta15170.","journal-title":"Health Technol Assess"},{"key":"362_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.7326\/M14-1152","volume":"162","author":"M Najafzadeh","year":"2015","unstructured":"Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162:407\u201319.","journal-title":"Ann Intern Med"},{"key":"362_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/cid\/civ220","volume":"61","author":"DB Rein","year":"2015","unstructured":"Rein DB, Wittenborn JS, Smith BD, et al. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis. 2015;61:157\u201368.","journal-title":"Clin Infect Dis"},{"key":"362_CR27","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/apt.13081","volume":"41","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Park H, Saab S, et al. Cost-effectiveness of all-oral ledipasvir\/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41:544\u201363.","journal-title":"Aliment Pharmacol Ther"},{"key":"362_CR28","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1136\/gutjnl-2014-307772","volume":"64","author":"R San Miguel","year":"2015","unstructured":"San Miguel R, Gimeno-Ballester V, Blazquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut. 2015;64:1277\u201388.","journal-title":"Gut"},{"key":"362_CR29","first-page":"1","volume":"24","author":"S Saab","year":"2016","unstructured":"Saab S, Paris\u00e9 H, Virabhak S, Wang A, Marx SE, Sanchez Gonzalez Y, Misurski D, Johnson S. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. J Med Econ. 2016;24:1\u201311 (Epub ahead of print).","journal-title":"J Med Econ."},{"key":"362_CR30","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","volume":"52","author":"AC Cardoso","year":"2010","unstructured":"Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652\u20137.","journal-title":"J Hepatol"},{"key":"362_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2165\/00019053-200927040-00006","volume":"27","author":"U Siebert","year":"2009","unstructured":"Siebert U, Sroczynski G, Aidelsburger P, et al. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics. 2009;27:341\u201354.","journal-title":"Pharmacoeconomics."},{"key":"362_CR32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.18553\/jmcp.2011.17.7.531","volume":"17","author":"C McAdam-Marx","year":"2011","unstructured":"McAdam-Marx C, McGarry LJ, Hane CA, et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17:531\u201346.","journal-title":"J Manag Care Pharm."},{"key":"362_CR33","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/apt.12625","volume":"39","author":"ZM Younossi","year":"2014","unstructured":"Younossi ZM, Kanwal F, Saab S, et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014;39:518\u201331.","journal-title":"Aliment Pharmacol Ther"},{"key":"362_CR34","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756\u201365.","journal-title":"Lancet"},{"key":"362_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1586\/erp.12.10","volume":"12","author":"X Gao","year":"2012","unstructured":"Gao X, Stephens JM, Carter JA, et al. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Rev Pharmacoecon Outcomes Res. 2012;12:335\u201343.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"362_CR36","first-page":"386A","volume":"58","author":"T Olufade","year":"2013","unstructured":"Olufade T, Devine S, Dutko F, et al. A cost-minimization analysis of ribavirin dose reduction versus erythropoietin based anemia management in treatment-naive genotype 1 chronic hepatitis C patients treated boceprevir plus peginterferon alfa & ribavirin. Hepatology. 2013;58:386A.","journal-title":"Hepatology"},{"key":"362_CR37","doi-asserted-by":"publisher","first-page":"e90295","DOI":"10.1371\/journal.pone.0090295","volume":"9","author":"AJ Brogan","year":"2014","unstructured":"Brogan AJ, Talbird SE, Thompson JR, et al. Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS One. 2014;9:e90295.","journal-title":"PLoS One"},{"key":"362_CR38","unstructured":"RED BOOK Online [database online]. Greenwood Village, CO: Truven Health Analytics Micromedex Solutions; 2014."},{"key":"362_CR39","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/apt.12880","volume":"40","author":"M Stepanova","year":"2014","unstructured":"Stepanova M, Nader F, Cure S, et al. Patients\u2019 preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther. 2014;40:676\u201385.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"362_CR40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T, The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24(2):289\u201393.","journal-title":"Hepatology."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0362-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-016-0362-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0362-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0362-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T22:45:12Z","timestamp":1748990712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-016-0362-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,24]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["362"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0362-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2016,6,24]]},"assertion":[{"value":"28 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2016","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}